Table 1.
Guideline Characteristics
| Author (year) | Organiz-ation | Primary conditiona | Focus | Region of origin | # of Committee membersi | #of Refs | Systematic search (Y/N) | Grading of evidence (Y/N) | Funding (NS, P, NC, G)j | Mean quality score |
|---|---|---|---|---|---|---|---|---|---|---|
| Zesiewicz et al. (2010) [35] | The American Academy of Neurology (AAN) | PD | Treatment | USA | 9 | 40 | Y | Y | NC | 4.5 |
| No Author (2010)b [37] | Scottish Intercollegiate Guidelines Network (SIGN) | PD | Diagnosis Treatment | Scotland | 20 | 189 | Y | Y | G | 6 |
| Grimes et al. (2012)c [34] | Canadian Neurological Sciences Federation (CNSF) & Parkinson Society Canada | PD | Diagnosis Treatment | Canada | 22 | 62 | Y | Y | NC & P | 6.5 |
| Berardelli et al. (2013) [38] | European Federation of Neurological Societies & Movement Disorder Society—European Section (EFNS-MDS-ES) | PD | Diagnosis | Europe | 25 | 245 | Y | Y | NS h | 5 |
| Ferreira et al. (2013) [40] | European Federation of Neurological Societies & Movement Disorder Society—European Section (EFNS-MDS-ES) | PD | Treatment | Europe | 22 | 363 | Y | Y | NC | 4.5 |
| Hort et al. (2010) [47] | European Federation of Neurological Societies (EFNS) | Dementia | Diagnosis Treatment | Europe | 8 | 100 | Y | Y | NC | 4.25 |
| No Author (2010) [42] | Ministry of Health, Social Services and Equality & Agency for Health Quality and Assessment of Catalonia (AIAQS) | Dementia | Diagnosis Treatment | Spain | 67 | 688 | Y | Y | NC & G | 5.75 |
| No Author (2011)d [41] | National Institute for Health and Care Excellence, National Collaborating Centre for Mental Health, British Psychological Society & The Royal College of Psychiatrists (NICE) | Dementia | Diagnosis & Treatment | UK | 28 | NNh | Y | Y | NC & G | 6.5 |
| Ihl et al. (2011) [44] | World Federation of Societies of Biological Psychiatry (WFSBP) | Dementia | Treatment | International | 39 | 215f | Y | Y | NC | 4.5 |
| No Author (2011) [43] | Clinical Research Centre for Dementia (CRCD) | Dementia | Diagnosis | South Korea | 20 | NNh | Y | Y | G | 5.25 |
| O’Brien et al. (2011) [60] | British Association of Psychopharmacology (BPA) | Dementia | Treatment | UK | 16 | 148f | N | Y | NC & P | 4 |
| Sorbi et al. (2012) [45] | European Federation of Neurological Societies & European Neurological Society (EFNS-ES) | Dementia | Diagnosis Treatment | Europe | 17 | 189 | Y | Y | NC | 4.5 |
| Gauthier et al (2012)e [50] | Canadian Consensus Conference on the Diagnosis and Treatment of Dementia (CCCDTD4) | Dementia | Diagnosis Treatment | Canada | 38 | 19 | Y | Y | NC | 5.5 |
| Gelenberg et al. (2010)g [39] | American Psychiatric Association (APA) | Depression | Treatment | USA | 7 | 1170 | Y | Y | NC | 4.75 |
| Dua et al. (2011) [49] | World Health Organization (WHO) | Mental Health | Diagnosis Treatment | International | 29 | 36 | Y | Y | NC & G | 5.5 |
| No Author (2012) [46] | Ministry of Health, Social Services and Equality & Galician Health Technology Assessment Agency (Availia-T) | Suicide | Diagnosis Treatment | Spain | 24 | 683 | Y | Y | NC & G | 5 |
| Mitchell et al. (2013) [48] | Institute for Clinical Systems Improvement (ICSI) | Depression | Diagnosis Treatment | USA | 14 | 331 | Y | Y | NC | 5.75 |
a Dementia guidelines primarily included Alzheimer’s disease, vascular dementia, general dementia care and one referred to Lewy Body Disease
b Includes Grosset et al. [54]
c Includes Patel et al. [61]
d Originally created in 2007 and updated in 2011
e Includes Moore et al. [62], Herrman et al. [63]
f Number counted from the text
g Includes Recommendations Referenced in Rabin et al. [64]
h NS: Not Stated, NN: Not Numbered
i Committee members—extracted from paper as listed (e.g. authors listed, guideline development/working groups etc.)
j NC: Non-Commercial, G: Government, Pharmaceutical, NS: Not Stated
References: The American Academy of Neurology (AAN) [35], Scottish Intercollegiate Guidelines Network (SIGN) [37, 54], Canadian Neurological Sciences Federation (CNSF) [34], Parkinson’s Society Canada [34], European Federation of Neurological Societies (EFNS) (n = 4) [38, 40, 45, 47], Movement Disorders Society-European Section (MDS-ES) [38, 40], National Institute for Health and Care Excellence (NICE) [41], Ministry of Health, Social Services and Equality & Agency for Health Quality and Assessment of Catalonia (AIAQS) [42], British Psychological Society [41], The Royal College of Psychiatrists [41], World Federation of Societies of Biological Psychiatry (WFSBP) [44], Clinical Research Centre for Dementia (CRCD), British Association of Psychopharmacology (BPA) [60], European Neurological Society, Canadian Consensus Conference on the Diagnosis and Treatment of Dementia (CCCDTD4) [50], American Psychiatric Association (APA) [39], World Health Organization (WHO) [49], Ministry of Health, Social Services and Equality & Galician Health Technology Assessment Agency (Availia-T) [46] and the Institute for Clinical Systems Improvement (ICSI) [48]